| Preliminary Program |
| Sunday,
December 15 |
|
| 14:00 |
Opening Remarks |
Joep Lange
University of Amsterdam, The Netherlands
Robert Murphy
Northwestern University, USA |
| DART Achievement
Award |
| 14:10 |
Presentation of the DART Achievement
Award in HIV Therapeutics |
Jean-Pierre Sommadossi
Idenix Pharmaceuticals, USA |
| 14:30 |
Analysis of viral reservoirs and
evolution during HAART |
Robert Siliciano
Johns Hopkins University School
of Medicine, USA |
| 15:10 |
Break |
|
STATE OF THE ART LECTURES
Pathogenesis and Mechanism of HIV Disease: Implications for
Therapeutic Strategies |
| Chairs |
Jean-Pierre Sommadossi
Idenix Pharmaceuticals, USA
Erik De Clercq
Katholieke Universiteit Leuven,
Belgium |
|
| 15:40 |
Revisiting HIV and cellular dynamics
using deuterated-glucose labeling |
Alan Perelson
Los Alamos National Laboratory,
USA |
| 16:20 |
Functional Genomic Analysis of
the Response to HAART in HIV-1-Infected Lymphatic Tissues |
Ashley Haase
University of Minnesota, USA |
| 17:00 |
Panel Discussion |
|
| 19:00 |
Welcome Reception – Poolside
|
|
| |
|
|
| Monday, December
16 |
|
| MORNING SESSION |
|
| Gertrude Elion Distinguished Lecturer
Award |
| 8:00 |
Presentation of Gertrude Elion
Distinguished Lecturer Award |
Raymond Schinazi
Emory University/Atlanta VA Medical
Center, USA
Robert Murphy
Northwestern University, USA |
| 8:10 |
Development and clinical evaluation
of Fuzeon (T-20): the first member of a novel class of anti-retroviral
agents that inhibit membrane fusion |
Dani Bolognesi
Trimeris, USA |
| Drug Discovery and Development:
Viral Targets |
| Chairs |
Raymond Schinazi
Emory University/ VA Medical
Center, USA
Paolo La Colla
Università di
Cagliari, Italy |
|
| 9:00 |
Drug discovery and development;
the bicyclam AMD3100, a case in point |
Erik De Clercq
Rega Institute for Medical Research,
Belgium |
| 9:20 |
The therapeutic potential
of Inhibiting HIV capsid core formation |
Peter Prevelige
University of Alabama at Birmingham,
USA |
| 9:40 |
Inhibition of HIV-1 Replication
Using RNA Interference |
Bryan Cullen
Duke University Medical Center,
USA |
| 10:00 |
Panel Discussion |
|
| 10:30 |
Morning Break |
|
| Drug Design: Biochemistry and Mechanism |
| Chairs |
Brendan Larder
Cambridge, UK
Eric Hunter
University of Alabama
at Birmingham, USA |
|
| 11:00 |
Antiretroviral therapy: past,
present, future -- will the third decade be the last? |
Sam Broder
Celera Genomics, USA |
| 11:20 |
Novel HIV-Specific Spirodiketopiperazine
CCR5 Inhibitors Potent against a Wide
Spectrum of R5-HIV
|
Hiroaki Mitsuya
National Cancer Institute, USA
|
| 11:45 |
How and When Incorporation Rate
and Binding Affinity of Nucleoside Analogues Are Major Determinants
of Drug-Resistance by HIV-RT: Common Features of Drug-Resistance
at the Molecular Level Mediated by L74V, K65R, Q151Mcomplex
and M184V RTn |
Bruno Canard
CNRS-AFMB, France |
| 12:00 |
Understanding the Anti-HIV Activity
of Dioxolane Nucleoside Analogues Against 3TC-Resistant HIV-1
Reverse Transcriptase |
David Chu
University of Georgia, USA |
| 12:15 |
Panel Discussion |
|
| 12:45 |
Lunch Break |
|
| |
|
|
| Satellite Symposium: Undulations
in the antiviral industry |
| Chairs |
Raymond Schinazi
Emory University/ VA
Medical Center, USA
Jean-Pierre Sommadossi
Idenix Pharmaceuticals,
USA |
|
| 14:00 |
Ansbert Gadicke,
Founding General Partner, MPM Capital, USA |
| |
Marina Bozilenko,
Managing Director and Global Head of Biotechnology, Banc of
America, USA |
| |
Kris Jenner,
Vice President, Portfolio Manager and Investment Analyst,
T. Rowe Price, USA |
| |
|
|
| MONDAY EVENING SESSION |
|
| Structural Biology and New Drug
Development |
| Chairs |
Franco Lori
Research Institute for Genetic and Human Therapy, Italy
David Chu
University of Georgia, USA |
|
| 16:30 |
Crystal structures of wild-type
HIV-2 & mutant HIV-1 reverse transcriptases and the mechanism
of resistance to non-nucleoside inhibitors |
David Stammers
University of Oxford, UK |
| 16:50 |
Mechanisms of Nucleoside Analog
Resistance |
Steve Hughes
National Cancer Institute, USA |
| 17:10 |
Development of next generation
NNRTIs and PIs |
Rudi Pauwels
Tibotec, Mechelen, Belgium |
| 17:30 |
Novel NNRTIs for HIV: Filling
the Gap |
Paolo La Colla
Università di Cagliari, Italy |
| 17:50 |
Panel Discussion |
|
| Oral Abstract Presentations |
| Chairs |
Jean-Louis Imbach
University of Montpellier,
France
Dennis Liotta
Emory University, USA |
|
| 18:25 |
Activity of the Cytidine Analog
Reverset (RVT) against 3TC-Resistant HIV-1 in SCID-hu Thy/Liv
Mice |
Cheryl Stoddart
Gladstone Institutes, USA |
| 18:40 |
Mannose-specific plant lectins
may qualify as efficient microbicides against human immunodeficiency
virus transmission |
Jan Balzarini
Rega Institute for Medical Research,
Belgiu |
| 18:55 |
Peptide Nucleic Acid (PNA) Targeted
to the Polypurine Tract (PPT) Sequence of Proviral HIV-1 DNA
Inhibits In Vitro HIV-1 Replication |
Alberto Bergamini
University of Rome, Italy |
| 19:10 |
CADA, a Novel Antiretroviral
drug with Specific CD4 Down-Modulating Activity
|
Kurt Vermeire
Rega Institute for Medical Research,
Belgium |
| 19:25 |
Panel Discussion |
|
| |
|
|
| Tuesday, December
17 |
|
| MORNING SESSION |
|
| Hurdles in Developing New Agents |
| Chairs |
Hiroaki Mitsuya
National Cancer Institute,
USA
Sam Broder
Celera Genomics, USA |
|
| 8:00 |
Drug resistance: progression &
transmission |
Douglas Richman
VA San Diego Healthcare System/University
of California San Diego, USA |
| 8:20 |
The role of pyrophosphorolysis
in drug resistance |
Walter Scott
University of Miami School of Medicine,
USA |
| 8:40 |
Challenges associated with the
development of drug resistance testing technologies for new
targets |
Christos Petropoulos
ViroLogic, Inc, USA |
| 9:00 |
Paradigms in viral genomic informatics |
Brendan Larder
Cambridge, UK |
| 9:20 |
Variations in drug resistance
patterns among HIV-1 subtypes |
Mark Wainberg
McGill University AIDS Centre, Canada |
| 9:35 |
Analysis of Patient-Derived HIV-1
Isolates Suggests a Novel Mechanism for Decreased Sensitivity
to Inhibition by Enfuvirtide and T-649 |
Eric Hunter
University of Alabama, Birmingham,
USA |
| 9:50 |
69S-XX Finger Insertion Mutations
in Combination with AZT-resistance Mutations in HIV-1 Reverse
Transcriptase: Effects on ATP-dependent Removal of ddA-monophosphate,
Sensitivity of the Removal reaction to Inhibition by dNTPs,
and DNA-dependent DNA Polymerization |
Peter Meyer
University of Miami, USA |
| 10:00 |
Panel Discussion |
|
| 10:30 |
Morning Break |
|
| Immunotherapy and Vaccines for
HIV Infection |
| Chairs |
Douglas Richman
VA San Diego Healthcare
System/University of California San Diego, USA
Tom Folks
Centers for Disease
Control and Prevention, USA
|
|
| 11:00 |
Virologic and immunologic challenges
in AIDS vaccine development |
Mark Feinberg
Emory University, USA |
| 11:20 |
DermaVir: a new topical DNA vaccine
for therapeutic management of HIV/AIDS |
Franco Lori
Research Institute for Genetic and
Human Therapy, Italy |
| 11:45 |
Biological Therapy of HIV/AIDS
Using HIV-Based Vectors Containing Anti-HIV Genetic Payloads |
Boro Dropulic
VIRxSYS Corporation, USA |
| 11:55 |
A Phase IIB Prospective, Randomized,
Contolled Study Evaluating the Immunomodulatory Role of Poly
I:Poly C12U Against HIV During STI |
Gary Blick
New York Medical College, USA |
| 12:05 |
Panel Discussion |
|
| 12:30 |
Lunch Break |
|
| |
Poster Reception, with wine and
hors d’oeuvres |
|
| |
|
|
| Wednesday, December
18 |
|
| MORNING SESSION |
|
| First Line Antiretroviral Therapy/Salvage
Therapy |
| Chairs |
Richard Pollard
University of California,
Davis Medical Center, USA
Carlos Zala
Fundación Huésped,
Argentina |
|
| 8:00 |
Determinants of therapeutic success
among patients initiating highly active antiretroviral therapy |
Julio Montaner
St. Paul’s Hospital, Canada |
| 8:20 |
Efficacy of MIV 310 in HIV
infected patients with NRTI resistant virus |
Christine Katlama
Groupe Hospitalier Pitié-Salpetrière,
France |
| 8:40 |
First line therapy strategies |
Robert Murphy
Northwestern University, USA |
| 9:00 |
Presentation |
Joep Lange
University of Amsterdam, The Netherlands |
| 9:20 |
Pharmacokinetic Drug Interaction
Screen Of Three Doses Of Tipranavir/Ritonavir (TPV/r) In HIV-Infected
Patients On Stable Highly Active Antiretroviral Therapy (HAART) |
Scott McCallister
Boehringer Ingelheim, USA |
| 9:35 |
Single and Multiple Dose Pharmacokinetics
and Safety of the Nucleoside Racivir® in Male Volunteers |
Mike Otto
Pharmasset, USA |
| 9:50 |
Efficacy and Safety of Amprenavir
(APV) and Ritonavir (RTV) Regimens in HIV-1 Infected Treatment-Experienced
Adults: 48-week data |
Robert Schooley
University of Colorado, USA |
| 10:05 |
Panel Discussion |
|
| 10:30 |
Morning Break |
|
| Oral Abstract Presentations |
| Chairs |
David Cooper
University of New
South Wales, Australia
José Gatell
Hospital Clinic, Spain |
|
| 11:00 |
Four Year Durability of the Antiretroviral
and Immunologic Effects of Lopinavir/ritonavir (Kaletra)-Based
Therapy in Treatment Naive Patients |
Robert Murphy
Northwestern University, USA |
| 11:15 |
Nelfinavir (NFV) Based HAART in
HIV Infected Patients with High Viral Loads |
Annkatrin Petersen
Pfizer Global Research and Development,
USA |
| 11:30 |
A Preliminary Clinical and Histological
Examination of Injection Site Reactions after Injections with
the HIV Fusion Inhibitor Enfuvirtide |
Sarah Myers
Duke University Medical Center,
USA |
| 11:45 |
Patch Testing as a Diagnostic
Modality in Patients Developing Presumed Drug-induced Hypersensitivity
Syndromes on Abacavir and Nonnucleoside Reverse Transcriptase
Inhibitors (NNRTIs) |
Elizabeth Phillips
Sunnybrook & Women's College
Health Sciences Center, USA |
| 12:00 |
Panel Discussion |
|
| 12:30 |
Lunch Break |
|
| |
|
|
| WEDNESDAY EVENING SESSION |
|
| Complications of Antiretroviral
Therapy: Basic to Clinical |
| Chairs |
Christine Katlama
Groupe Hospitalier Pitié-Salpetrière,
France
Joep Lange
University of Amsterdam,
The Netherlands |
|
| 16:30 |
Basic mitochondrial toxicity |
Lieven Stuyver
Pharmasset, Inc, USA |
| 16:50 |
Mitochondrial toxicity of antiviral
nucleoside analogs: insight from in vivo studies with transgenic
mice
|
William Lewis
Emory University, USA |
| 17:10 |
Mitochondrial toxicity in the
era of HAART |
Julio Montaner
St. Paul’s Hospital, Canada
|
| 17:30 |
Protease toxicity |
David Cooper
University of New South Wales, Australia |
| 17:50 |
Measuring mtDNA and mtRNA Levels
in PBMC: a Powerful Tool to Assess Mitochondrial Toxicity
of Antiviral Drugs |
Bob van Gemen
Primagen, The Netherlands |
| 18:05 |
Panel Discussion |
|
| 20:00 |
Gala Event
|
|
| |
|
|
| Thursday, December
19 |
|
| MORNING SESSION |
|
| HIV/Hepatitis and Other Co-Infections |
| Chairs |
Robert Murphy
Northwestern University,
USA
Julio Montaner
St. Paul’s Hospital,
Canada |
|
| 8:00 |
HIV/HCV – Disease and modern
treatments |
Yves Benhamou
Hopital Pitie-Salpetriere, France |
| 8:30 |
Co-Infection with HBV and HIV |
Bruce Polsky
St. Luke's-Roosevelt Hospital Center
and Columbia University College of Physicians and Surgeons,
USA |
| 8:50 |
HIV and HCV Co-Infection Among
Young Injection Drug Users |
Cari Miller
BC Centre for Excellence in HIV/AIDS,
Canada |
| 9:05 |
Pharmacokinetics and Safety of
NFV Based Anti-Retroviral Therapy (ARV) in HIV-Infected Patients
with Hepatitis and Other Hepatic Dysfunction |
Mark Becker
Agouron Pharmaceuticals, USA |
| 9:20 |
Pharmacokinetics and safety of
the nucleoside Reverset in HIV-1 infected patients |
Michael Otto
Pharmasset, USA |
| 9:30 |
ACH-126,443 (Beta-L-Fd4C) shows
potent anti-HIV activity in proof-of-principle study in treatment-experienced
patients with M184V and other reverse transcriptase
mutations |
Lisa Dunkle
Achillion Pharmaceuticals, USA |
| 9:40 |
Panel Discussion |
|
| 10:15 |
Morning Break |
|
| Assessing the Benefits or Damages
of Treatment Interruptions |
| Chairs |
Bruce Polsky
St. Luke's-Roosevelt Hospital
Center and Columbia University College of Physicians
and Surgeons, USA
Yves Benhamou
Hopital Pitie-Salpetriere,
France |
|
| 10:45 |
Structured treatment interruptions
fail to enhance viraemic control in chronic HIV infection |
Rodney Phillips
The Peter Medawar Building for Pathogen
Research, UK |
| 11:05 |
Benefits and risks of treatment
interruption strategies |
Mark Dybul
National Institute of Allergy and
Infectious Diseases, USA |
| 11:25 |
The addition of mycophenolate
mophetil (MMF) to HAART in early stage HIV- infected patients
is associated with a probable decrease in viral reservoir
size |
José Gatell
Hospital Clinic, Spain |
| 11:45 |
Panel Discussion |
|
| 12:15 |
Closing Remarks |
Joep Lange
Raymond Schinazi
|
